在其他市场中该基金则希望或多或少的打破平衡。
The companies beneficence may reap long-term rewards, however.
但是公司的利益可能是长期回报。
For some time they have been seeking to expand their presence beyond Japan s shores.
有时他们在寻求途径希望自己的定位不仅仅是日本企业。
In 2011 Takeda bought Nycomed, a Swiss drugmaker, for about 14 billion.
2011年Takeda以140亿美金的价格买下了瑞士制药厂Nycomed。
In 2008 Daiichi Sankyo spent nearly 5 billion on Ranbaxy, an Indian drugmaker that has sincebeen plagued by safety issues.
2008年Daiichi Sankyo投资近50亿在Ranbaxy。这是一家因为安全问题惹上麻烦的印度制药公司。
The GHIT Fund will be a far smaller, and less controversial, investment.
GHIT基金会成为缩小规模减少争议的组织。
But it will help the firms build links with prestigious research institutions in America andEurope, and eventually introduce Japanese drug brands to patients, and health ministries, inemerging markets.
但他会帮助公司与欧美知名研究机构建立联系,并最终让新兴市场的病人和卫生部知道日本品牌。
【2015考研英语阅读药物】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30